Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6966533 | 1.00 | CA14 (0.58) | CA14CA12SMN1; SMN2TSHRCA7 | |
| SCHEMBL13204470 | 1.00 | CA14 (0.58) | CA14CA12SMN1; SMN2TSHRCA7 | |
| Hydrochloric Acid SCHEMBL17559741 | 0.97 | CA14 (0.56) | CA14CA12SMN1; SMN2TSHRCA7 | |
| Hydrochloric Acid SCHEMBL1761465 | 0.97 | CA14 (0.56) | CA14CA12SMN1; SMN2TSHRCA7 | |
| Hydrochloric Acid SCHEMBL29398016 | 0.97 | CA14 (0.56) | CA14CA12SMN1; SMN2TSHRCA7 | |
| SCHEMBL24445693 | 0.82 | CA14 (0.45) | CA14CA12SMN1; SMN2TSHRCA7 | |
| SCHEMBL8164724 | 0.82 | CA14 (0.45) | CA14CA12SMN1; SMN2TSHRCA7 | |
| SCHEMBL24556376 | 0.82 | CA14 (0.45) | CA14CA12SMN1; SMN2TSHRCA7 | |
| SCHEMBL10654071 | 0.82 | CA12 (0.40) | CA14CA12SMN1; SMN2TSHRCA7 | |
| SCHEMBL9925882 | 0.82 | CA14 (0.45) | CA14CA12SMN1; SMN2TSHRCA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624053-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260070930-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-03-12 | — | — | US | disclosed |
| EP-4688790-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688789-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028353-A1 | MACROCYCLIC RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-01-29 | — | — | US | disclosed |
| US-20250388608-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-12-25 | — | — | US | disclosed |
| US-20250368661-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
| CN-101583352-A | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORP (US) | 2009-11-18 | — | — | CN | disclosed |
| US-7553969-B1 | Substituted phenethylamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553969-B1 | Substituted phenethylamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-30 | — | — | US | disclosed |
| WO-2007049803-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2007-05-03 | — | — | WO | disclosed |
| WO-2004080976-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
| US-4668683-A | Cardiotonic quinazoline derivatives | KYOWA HAKKO KOGYO K.K. (JP) | 1987-05-26 | — | — | US | disclosed |
| EP-0195667-A2 | Cardiotonic quinazoline derivatives | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1986-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368661-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CA14 3948/4885CA12 4023/4885SMN1; SMN2 3728/4885 |
| US-20260070930-A1 | RAS INHIBITORS | KRAS, NRAS, RIN1 | CA14 4565/4885CA12 3608/4885SMN1; SMN2 4241/4885 |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | CA14 2063/4885CA12 1947/4885SMN1; SMN2 3650/4885 |
| US-20260028353-A1 | MACROCYCLIC RAS INHIBITORS | KRAS, NRAS, HRAS | CA14 3262/4885CA12 3386/4885SMN1; SMN2 3943/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | CA14 4556/4885CA12 4480/4885SMN1; SMN2 986/4885 |
| US-12624053-B2 | Ras inhibitors | KRAS, NRAS, HMGCR | CA14 4511/4885CA12 4070/4885SMN1; SMN2 4495/4885 |
| US-20250388608-A1 | RAS INHIBITORS | KRAS, NRAS, HMGCR | CA14 4511/4885CA12 4070/4885SMN1; SMN2 4495/4885 |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BCAT2, BCAT1, FABP4 | CA14 4718/4885CA12 4717/4885SMN1; SMN2 4427/4885 |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BCAT2, BCAT1, FABP4 | CA14 4718/4885CA12 4717/4885SMN1; SMN2 4427/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | CA14 4431/4885CA12 4350/4885SMN1; SMN2 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.